What is AIM IMMUNOTECH INC's earnings per share (EPS)?

AIM IMMUNOTECH INC (AIMI) reported diluted earnings per share of -$8.62 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AIM IMMUNOTECH INC (AIMI) Financials

AIMI

Trailing 12 months to March 31, 2026

Revenue $94K -35.6% YoY

Net Income -$13.3M +12.7% YoY

EPS (Diluted) -$8.62 FY2025 annual

Operating Cash Flow -$11.3M +9.0% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2026, ended Mar 31, 2026 Reported May 15, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q1 FY2026, filed May 15, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AIMI SEC filings page.

AIM IMMUNOTECH INC (AIMI) reported $94K in revenue over the twelve months to Mar 31, 2026, down 35.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI AIMI FY2025 2026-08-30

AIM ImmunoTech operates as a development-stage business where funding inflows, not revenue, finance recurring operating cash consumption.

Operating loss narrowed from -$19.8M in FY2024 to -$11.7M in FY2025 even as revenue fell, indicating expense contraction rather than commercial scale. Meanwhile, financing supplied $10.4M against operating cash flow of -$11.0M, linking the improved cash gap to external funding rather than internally generated cash.

Development spending dominates monetization: R&D was $3.9M against only $88K of FY2025 revenue. R&D also declined from $6.2M in FY2024, helping reduce the operating loss but not establishing a revenue engine.

The current ratio fell from 1.7x in FY2023 to 0.5x in FY2025, meaning current liabilities now exceed current assets and short-term flexibility has narrowed. By FY2025, total liabilities of $15.6M exceeded total assets of $5.8M, leaving negative equity and making financing structure more consequential than conventional profitability ratios.

Financial Health Signals

Financial health score not available

AIM IMMUNOTECH INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Altman Z-Score Distress

-113.90

AIM IMMUNOTECH INC scores -113.90, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.0M) relative to total liabilities ($15.6M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

AIM IMMUNOTECH INC passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

AIM IMMUNOTECH INC reported a net loss of $14.0M while operations used $11.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

AIM IMMUNOTECH INC reported an operating loss of $11.7M against $812K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$22K

YoY+37.5%

QoQ+4.8%

5Y CAGR-4.7%

AIM IMMUNOTECH INC generated $22K in revenue in Q1 2026. This represents an increase of 37.5% from the same quarter a year earlier. Against the prior quarter it is up 4.8%.

EBITDA

-$2.2M

YoY+38.7%

AIM IMMUNOTECH INC's EBITDA was -$2.2M in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 38.7% from the same quarter a year earlier.

Net Income

-$3.0M

YoY+18.4%

QoQ+27.6%

AIM IMMUNOTECH INC reported -$3.0M in net income in Q1 2026. This represents an increase of 18.4% from the same quarter a year earlier. Against the prior quarter it is up 27.6%.

EPS (Diluted)

-$0.69

AIM IMMUNOTECH INC earned -$0.69 per diluted share (EPS) in Q1 2026.

Cash & Balance Sheet

Cash & Debt

$5.8M

YoY+547.7%

QoQ+94.8%

5Y CAGR-34.6%

10Y CAGR+19.1%

AIM IMMUNOTECH INC held $5.8M in cash against $210K in long-term debt as of Q1 2026, with $6.1M of liabilities due within a year.

Shares Outstanding

5Y CAGR-29.8%

10Y CAGR-28.9%

AIM IMMUNOTECH INC had 8M shares outstanding in Q1 2026.

Free Cash Flow

Not reported for Q1 2026.

Dividends Per Share

Not reported for Q1 2026.

Margins & Returns

Return on Equity

-142.3%

AIM IMMUNOTECH INC's ROE was -142.3% in Q1 2026, measuring profit generated per dollar of shareholder equity.

Gross Margin

Not reported for Q1 2026.

Operating Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q1 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending

$482K

YoY-55.4%

QoQ-54.7%

5Y CAGR-19.5%

AIM IMMUNOTECH INC invested $482K in research and development in Q1 2026. This represents a decrease of 55.4% from the same quarter a year earlier. Against the prior quarter it is down 54.7%.

Share Buybacks

Not reported for Q1 2026.

Capital Expenditures

Not reported for Q1 2026.

AIMI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AIMI quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$94K	$88K-48.2%	$170K-15.8%	$202K+43.3%	$141K+4.4%	$135K-17.2%	$163K+16.4%	$140K-61.9%	$367K-16.0%	$437K+375.0%	$92K-30.8%	$133K-32.5%	$197K+31.3%	$150K-29.6%	$213K+32.3%	$161K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.3M+1.4%	$1.2M-38.0%	$2.0M+90.7%	$1.0M
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-$1.1M+2.8%	-$1.1M+39.0%	-$1.8M-101.4%	-$882K
R&D Expenses	$3.3M	$3.9M-36.7%	$6.2M-43.3%	$10.9M+56.5%	$7.0M-8.9%	$7.7M+34.1%	$5.7M+23.0%	$4.7M-2.7%	$4.8M+16.6%	$4.1M-19.8%	$5.1M-36.5%	$8.0M-10.6%	$9.0M+7.5%	$8.4M-12.1%	$9.5M+41.4%	$6.7M
SG&A Expenses	$6.9M	$7.7M-43.9%	$13.7M-35.1%	$21.1M+61.7%	$13.1M+50.8%	$8.7M+0.2%	$8.7M+22.9%	$7.0M+13.5%	$6.2M-5.6%	$6.6M-14.4%	$7.7M+7.5%	$7.1M-21.1%	$9.1M+17.3%	$7.7M-14.7%	$9.1M+35.3%	$6.7M
Operating Income	-$10.3M	-$11.7M+41.0%	-$19.8M+38.0%	-$31.9M-60.2%	-$19.9M-5.8%	-$18.8M-24.3%	-$15.2M-21.8%	-$12.4M-8.2%	-$11.5M-0.7%	-$11.4M+17.3%	-$13.8M+17.1%	-$16.6M+12.8%	-$19.1M-11.3%	-$17.2M+15.6%	-$20.3M-42.3%	-$14.3M
EBITDA	N/A	-$11.5M+41.3%	-$19.5M+38.4%	-$31.7M-61.1%	-$19.7M-8.9%	-$18.1M-25.3%	-$14.4M-23.8%	-$11.7M-9.7%	-$10.6M-2.0%	-$10.4M+17.6%	-$12.6M+19.4%	-$15.7M+14.8%	-$18.4M-12.9%	-$16.3M+17.2%	-$19.7M-42.4%	-$13.8M
Interest Expense	$992K	$812K+38.8%	$585K	N/A	N/A	$67K-90.0%	$672K+57.4%	$427K+112.4%	$201K+44.6%	$139K	N/A	$3K-72.7%	$11K-31.3%	$16K-33.3%	$24K-41.5%	$41K
Net Income	-$13.3M	-$14.0M+19.4%	-$17.3M+40.2%	-$29.0M-48.9%	-$19.4M-1.7%	-$19.1M-32.8%	-$14.4M-53.1%	-$9.4M+4.3%	-$9.8M-19.0%	-$8.3M-10.1%	-$7.5M+50.7%	-$15.2M+12.7%	-$17.4M-7.6%	-$16.2M+6.5%	-$17.4M-92.5%	-$9.0M
EPS (Basic)	N/A	-$8.62+72.1%	-$30.92-5053.3%	-$0.60-50.0%	-$0.400.0%	-$0.40	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	—	-$8.62	-$30.92	-$0.60-50.0%	-$0.40	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	2M	560,169	49M+1.1%	48M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Revenue	$22K+37.5%	$21K-53.3%	$26K-25.7%	$25K-50.0%	$16K-60.0%	$45K-30.8%	$35K-23.9%	$50K+19.0%
R&D Expenses	$482K-55.4%	$1.1M-36.1%	$607K-57.8%	$1.2M+2.5%	$1.1M-44.6%	$1.7M-48.0%	$1.4M-47.4%	$1.1M-61.2%
SG&A Expenses	$1.8M-30.8%	$1.9M-55.8%	$1.8M-41.6%	$1.5M-42.6%	$2.5M-33.3%	$4.2M-61.0%	$3.1M-43.4%	$2.6M+1.6%
Operating Income	-$2.2M+38.5%	-$3.0M+49.6%	-$2.4M+45.5%	-$2.6M+28.4%	-$3.6M+36.9%	-$5.9M+58.2%	-$4.5M+45.0%	-$3.7M+32.4%
EBITDA	-$2.2M+38.7%	N/A	N/A	N/A	-$3.6M+37.3%	N/A	N/A	N/A
Interest Expense	$304K+145.2%	$391K+196.2%	$148K-26.7%	$149K-16.8%	$124K+72.2%	$132K	$202K	$179K
Net Income	-$3.0M+18.4%	-$4.2M+30.0%	-$3.3M+11.2%	-$2.8M-52.2%	-$3.7M+36.3%	-$6.0M+52.6%	-$3.7M+52.7%	-$1.8M+62.6%
EPS (Basic)	-$0.69-1280.0%	N/A	$1.57+126.2%	-$3.68-22.7%	-$0.05+58.3%	N/A	-$6.00-3650.0%	-$3.00-2900.0%
EPS (Diluted)	-$0.69	N/A	$1.57	-$3.68	-$0.05	N/A	-$6.00	-$3.00
Diluted Shares (Avg)	4M	N/A	2M	759,289	703,298	N/A	576,770	528,374

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

AIMI Balance Sheet

AIMI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$5.8M-32.8%	$8.6M-55.6%	$19.4M-52.1%	$40.5M-29.8%	$57.7M-10.7%	$64.6M+211.2%	$20.8M+49.9%	$13.8M-2.5%	$14.2M-24.7%	$18.9M-17.2%	$22.8M-22.5%	$29.4M-7.6%	$31.9M-44.8%	$57.7M+32.6%	$43.5M
Current Assets	$3.3M-21.1%	$4.2M-71.3%	$14.6M-59.9%	$36.3M-27.7%	$50.2M+24.6%	$40.3M+285.9%	$10.4M+175.0%	$3.8M+8.4%	$3.5M-49.5%	$6.9M-34.3%	$10.6M-36.0%	$16.5M-11.0%	$18.6M-58.5%	$44.7M+40.7%	$31.8M
Cash & Equivalents	$3.0M+75.5%	$1.7M-68.7%	$5.4M-79.9%	$27.1M-15.7%	$32.1M-16.6%	$38.5M+2519.1%	$1.5M+391.6%	$299K-78.8%	$1.4M-41.4%	$2.4M+13.9%	$2.1M-1.9%	$2.2M+168.5%	$803K-63.7%	$2.2M-28.7%	$3.1M
Short-Term Investments	$62K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$7K	N/A	$1.2M-29.4%	$1.7M	N/A	$34K-22.7%	$44K-81.3%	$235K+879.2%	$24K	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$15.6M+56.7%	$9.9M+8.6%	$9.1M+352.8%	$2.0M+146.3%	$820K-75.1%	$3.3M-55.0%	$7.3M-11.5%	$8.3M+50.2%	$5.5M+63.1%	$3.4M+38.7%	$2.4M-45.2%	$4.4M+72.7%	$2.6M-80.2%	$13.0M+134.3%	$5.5M
Current Liabilities	$6.2M-34.7%	$9.5M+10.2%	$8.7M+535.7%	$1.4M+102.2%	$673K-38.9%	$1.1M-2.2%	$1.1M-78.7%	$5.3M+95.5%	$2.7M+11.2%	$2.4M+0.1%	$2.4M-45.2%	$4.4M+75.2%	$2.5M-80.0%	$12.6M+149.5%	$5.1M
Non-Current Liabilities	$9.3M+2264.8%	$395K-20.2%	$495K-24.9%	$659K+348.3%	$147K-93.3%	$2.2M-64.6%	$6.2M+108.0%	$3.0M+6.3%	$2.8M+197.6%	$940K	$0	$0-100.0%	$37K-89.4%	$350K-26.9%	$479K
Long-Term Debt	$927K-67.0%	$2.8M	N/A	N/A	N/A	$1.9M-10.8%	$2.1M-9.2%	$2.3M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$9.8M-640.0%	-$1.3M-112.9%	$10.2M-73.4%	$38.5M-32.4%	$56.9M-7.2%	$61.3M+356.0%	$13.4M+140.9%	$5.6M-35.9%	$8.7M-43.8%	$15.5M-23.9%	$20.4M-18.5%	$25.0M-14.7%	$29.3M-34.5%	$44.7M+17.7%	$38.0M
Retained Earnings	-$440.8M-3.3%	-$426.8M-4.2%	-$409.5M-7.6%	-$380.5M-5.4%	-$361.1M-5.6%	-$342.0M-4.4%	-$327.6M-2.8%	-$318.6M-3.2%	-$308.8M-2.7%	-$300.5M-2.6%	-$293.0M-5.5%	-$277.8M-6.7%	-$260.3M-6.6%	-$244.1M-7.7%	-$226.7M

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Total Assets	$8.6M+37.4%	$5.8M-32.8%	$5.5M-59.6%	$4.1M-73.7%	$6.2M-61.4%	$8.6M-55.6%	$13.6M-51.2%	$15.7M-53.3%
Current Assets	$6.2M+140.5%	$3.3M-21.1%	$2.6M-66.0%	$1.0M-90.1%	$2.6M-77.1%	$4.2M-71.3%	$7.6M-66.7%	$10.4M-64.1%
Cash & Equivalents	$5.8M+547.7%	$3.0M+75.5%	$2.3M+156.5%	$476K-86.6%	$898K-72.7%	$1.7M-68.7%	$915K-94.0%	$3.6M-83.1%
Accounts Receivable	N/A	$7K	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$6.5M-36.1%	$15.6M+56.7%	$11.6M+8.4%	$10.7M+11.0%	$10.1M-11.1%	$9.9M+8.6%	$10.7M+103.0%	$9.6M+176.1%
Current Liabilities	$6.1M-37.1%	$6.2M-34.7%	$4.0M-60.0%	$10.4M+17.5%	$9.8M-1.1%	$9.5M+10.2%	$10.1M+114.2%	$8.8M+206.5%
Non-Current Liabilities	$315K-6.8%	$9.3M+2264.8%	$7.5M+1206.9%	$282K-63.4%	$338K-77.3%	$395K-20.2%	$576K+6.1%	$771K+29.1%
Long-Term Debt	$210K-91.2%	$927K-67.0%	N/A	$2.7M+861.5%	$2.4M+151.2%	$2.8M	$139K	$283K
Total Equity	$2.1M+155.1%	-$9.8M-640.0%	-$6.1M-308.7%	-$6.5M-207.3%	-$3.9M-179.9%	-$1.3M-112.9%	$2.9M-87.1%	$6.1M-79.8%
Retained Earnings	-$443.8M-3.1%	-$440.8M-3.3%	-$436.6M-3.7%	-$433.3M-3.9%	-$430.5M-3.7%	-$426.8M-4.2%	-$420.9M-6.0%	-$417.2M-7.2%

Not reported in any period shown, so not listed: Short-Term Investments, Inventory, Long-Term Investments, Goodwill.

AIMI Cash Flow Statement

AIMI quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$11.3M	-$11.0M+26.4%	-$14.9M+30.0%	-$21.3M-32.0%	-$16.1M-15.3%	-$14.0M-34.7%	-$10.4M-14.3%	-$9.1M+14.8%	-$10.6M-34.0%	-$7.9M-7.6%	-$7.4M+54.0%	-$16.1M-15.0%	-$14.0M+17.0%	-$16.8M-28.1%	-$13.1M-30.1%	-$10.1M
Depreciation & Amortization	N/A	$210K-14.6%	$246K+3.4%	$238K-7.0%	$256K-67.0%	$775K+5.7%	$733K-7.4%	$792K-9.8%	$878K-12.5%	$1.0M-14.1%	$1.2M+19.9%	$975K+40.1%	$696K-19.7%	$867K+34.8%	$643K+38.3%	$465K
Stock-Based Compensation	N/A	$60K-91.3%	$686K+182.3%	$243K-74.5%	$954K-39.2%	$1.6M+51.4%	$1.0M+21.5%	$853K-8.2%	$929K+62.7%	$571K+998.1%	$52K-57.0%	$121K-45.7%	$223K+1.8%	$219K-19.2%	$271K0.0%	$271K
Capital Expenditures	N/A	N/A	$18K	N/A	$86K+109.8%	$41K+86.4%	$22K-67.6%	$68K+33.3%	$51K+155.0%	$20K-87.5%	$160K-33.3%	$240K-52.4%	$504K-43.9%	$898K-84.4%	$5.8M+219.4%	$1.8M
Free Cash Flow	N/A	N/A	-$14.9M	N/A	-$16.2M-15.6%	-$14.0M-34.8%	-$10.4M-13.7%	-$9.1M+14.6%	-$10.7M-34.3%	-$8.0M-5.6%	-$7.5M+53.7%	-$16.3M-12.6%	-$14.5M+18.4%	-$17.7M+6.2%	-$18.9M-58.8%	-$11.9M
Investing Cash Flow	$918K	$1.9M-60.6%	$4.7M+665.6%	-$832K-107.6%	$11.0M+1841.4%	-$631K+93.1%	-$9.2M-49.1%	-$6.1M-6781.5%	$92K-96.6%	$2.7M-6.4%	$2.9M-54.1%	$6.4M+150.9%	$2.5M-88.6%	$22.3M+238.6%	-$16.1M-285.6%	$8.7M
Financing Cash Flow	$15.3M	$10.4M+61.2%	$6.4M+1228.7%	$485K+506.3%	$80K-99.0%	$8.2M-85.5%	$56.6M+245.2%	$16.4M+73.7%	$9.4M+123.8%	$4.2M-11.4%	$4.8M-50.8%	$9.7M-24.4%	$12.8M+286.7%	-$6.8M-124.2%	$28.3M+1643.3%	$1.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$135K	N/A	$388K	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Operating Cash Flow	-$2.7M-15.2%	-$2.0M+49.8%	-$5.1M-63.3%	-$1.5M+49.1%	-$2.4M+51.0%	-$4.0M+59.5%	-$3.1M+45.2%	-$3.0M-39.4%
Depreciation & Amortization	$43K-25.9%	N/A	N/A	N/A	$58K0.0%	N/A	N/A	N/A
Stock-Based Compensation	$0-100.0%	N/A	$0-100.0%	$0-100.0%	$60K-25.0%	N/A	$80K+60.0%	$80K+60.0%
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	$0	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	-$4.0M	N/A	N/A
Investing Cash Flow	-$37K-104.1%	-$95K-102.6%	$296K-11.4%	$754K-8.7%	$898K+668.4%	$3.7M+1830.8%	$334K+199.4%	$826K+504.9%
Financing Cash Flow	$5.6M+746.5%	$2.7M+162.2%	$6.7M+4756.9%	$355K-85.5%	$660K-76.7%	$1.0M+605.4%	$137K-41.2%	$2.4M+48720.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

AIMI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

AIMI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-535.0%	-722.7%	-833.8%	-547.8%
Operating Margin	-13254.6%	-11630.6%	-15800.0%	-14129.8%	-13954.1%	-9295.7%	-8887.9%	-3132.4%	-2612.4%	-15004.3%	-12518.8%	-9694.9%	-11444.7%	-9549.3%	-8878.9%
Net Margin	-15861.4%	-10188.2%	-14337.6%	-13790.8%	-14168.1%	-8834.4%	-6717.1%	-2677.7%	-1889.9%	-8154.3%	-11451.1%	-8857.9%	-10816.7%	-8147.4%	-5599.4%
Return on Equity	N/A	N/A	-283.0%-232.4pp	-50.5%-16.9pp	-33.6%-10.1pp	-23.5%+46.5pp	-70.0%+106.2pp	-176.1%-81.2pp	-94.9%-46.5pp	-48.4%+26.4pp	-74.8%-5.0pp	-69.8%-14.4pp	-55.4%-16.6pp	-38.8%-15.1pp	-23.8%
Return on Assets	-241.4%-40.2pp	-201.2%-51.8pp	-149.4%-101.4pp	-48.0%-14.9pp	-33.1%-10.9pp	-22.3%+23.0pp	-45.3%+25.7pp	-71.0%-12.8pp	-58.1%-18.4pp	-39.8%+27.0pp	-66.8%-7.5pp	-59.3%-8.4pp	-50.9%-20.8pp	-30.1%-9.4pp	-20.7%
Current Ratio	0.53+0.1x	0.44-1.2x	1.68-25.0x	26.69-47.9x	74.61+38.0x	36.58+27.3x	9.27+8.6x	0.72-0.6x	1.29-1.6x	2.85-1.5x	4.34+0.6x	3.72-3.6x	7.33+3.8x	3.54-2.7x	6.27
Debt-to-Equity	N/A	N/A	0.89+0.8x	0.050.0x	0.010.0x	0.03-0.1x	0.16-0.3x	0.42-0.2x	0.63+0.4x	0.22+0.1x	0.12-0.1x	0.18+0.1x	0.09-0.2x	0.29+0.1x	0.15
Asset Turnover	0.020.0x	0.020.0x	0.010.0x	0.000.0x	0.000.0x	0.000.0x	0.010.0x	0.030.0x	0.030.0x	0.000.0x	0.010.0x	0.010.0x	0.000.0x	0.000.0x	0.00
FCF Margin	N/A	-8768.2%	N/A	-11485.1%	-10374.8%	-6374.2%	-6525.0%	-2913.1%	-1821.7%	-8195.7%	-12250.4%	-7344.2%	-11818.7%	-8869.0%	-7390.1%

Metric	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'25	Q1'2510-Q	Q4'2410-K	Q3'2410-Q	Q2'24
Operating Margin	-10118.2%	-14057.1%	-9411.5%	-10584.0%	-22618.8%	-13011.1%	-12825.7%	-7388.0%
Net Margin	-13740.9%	-19881.0%	-12630.8%	-11176.0%	-23156.3%	-13260.0%	-10571.4%	-3672.0%
Return on Equity	-142.3%	N/A	N/A	N/A	N/A	N/A	-127.1%-92.5pp	-30.1%-13.8pp
Return on Assets	-35.2%+24.1pp	-72.2%-2.9pp	-59.8%-32.5pp	-67.7%-56.0pp	-59.3%-23.4pp	-69.3%-4.4pp	-27.2%+0.8pp	-11.7%+2.9pp
Current Ratio	1.01+0.7x	0.53+0.1x	0.64-0.1x	0.10-1.1x	0.26-0.9x	0.44-1.2x	0.75-4.1x	1.17-8.8x
Debt-to-Equity	0.10	N/A	N/A	N/A	N/A	N/A	0.05-0.2x	0.05-0.1x
Asset Turnover	0.000.0x	0.000.0x	0.000.0x	0.010.0x	0.000.0x	0.010.0x	0.000.0x	0.000.0x
FCF Margin	N/A	N/A	N/A	N/A	N/A	-8788.9%	N/A	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$9.8M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.53), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
AIM IMMUNOTECH INC AIMI	FY2025	$88K	-$14.0M	N/A	$2.0M	—
SORRENTO THERAPEUTICS INC SRNE	FY2022	$62.8M	-$572.8M	N/A	$1.9M	—

Where AIM IMMUNOTECH INC Ranks

Frequently Asked Questions

What is AIM IMMUNOTECH INC's annual revenue?

AIM IMMUNOTECH INC (AIMI) reported $88K in total revenue for fiscal year 2025. This represents a -48.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AIM IMMUNOTECH INC's revenue growing?

AIM IMMUNOTECH INC (AIMI) revenue declined by 48.2% year-over-year, from $170K to $88K in fiscal year 2025.

Is AIM IMMUNOTECH INC profitable?

No, AIM IMMUNOTECH INC (AIMI) reported a net income of -$14.0M in fiscal year 2025.

What is AIM IMMUNOTECH INC's EBITDA?

AIM IMMUNOTECH INC (AIMI) had EBITDA of -$11.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does AIM IMMUNOTECH INC have?

As of fiscal year 2025, AIM IMMUNOTECH INC (AIMI) had $3.0M in cash and equivalents against $927K in long-term debt.

What is AIM IMMUNOTECH INC's operating cash flow?

AIM IMMUNOTECH INC (AIMI) recorded an outflow of $11.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are AIM IMMUNOTECH INC's total assets?

AIM IMMUNOTECH INC (AIMI) had $5.8M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does AIM IMMUNOTECH INC spend on research and development?

AIM IMMUNOTECH INC (AIMI) invested $3.9M in research and development during fiscal year 2025.

How many shares does AIM IMMUNOTECH INC have outstanding?

AIM IMMUNOTECH INC (AIMI) had 3M shares outstanding as of fiscal year 2025.

What is AIM IMMUNOTECH INC's current ratio?

AIM IMMUNOTECH INC (AIMI) had a current ratio of 0.53 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is AIM IMMUNOTECH INC's return on assets (ROA)?

AIM IMMUNOTECH INC (AIMI) had a return on assets of -241.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is AIM IMMUNOTECH INC's debt-to-equity ratio negative or not reported?

AIM IMMUNOTECH INC (AIMI) has negative shareholder equity of -$9.8M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is AIM IMMUNOTECH INC's Altman Z-Score?

AIM IMMUNOTECH INC (AIMI) has an Altman Z-Score of -113.90, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is AIM IMMUNOTECH INC's Piotroski F-Score?

AIM IMMUNOTECH INC (AIMI) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AIM IMMUNOTECH INC's earnings high quality?

AIM IMMUNOTECH INC (AIMI) reported a net loss of $14.0M while operations used $11.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can AIM IMMUNOTECH INC cover its interest payments?

AIM IMMUNOTECH INC (AIMI) reported an operating loss of $11.7M against $812K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.